Literature DB >> 20200430

TP53, MDM2, NQO1, and susceptibility to cervical cancer.

Xiaoxia Hu1, Zhengyan Zhang, Duanduan Ma, Phyllis C Huettner, L Stewart Massad, Loan Nguyen, Ingrid Borecki, Janet S Rader.   

Abstract

Host genetic variability modifies the risk of cervical cancer in women infected with oncogenic human papillomavirus (HPV). Studies have reported an association of the TP53 codon 72 arginine and cervical cancer, but the results are inconsistent. We examined the association of this single nucleotide polymorphism (SNP) in women with cervical cancer and cervical intraepithelial neoplasia grade 3, using a family-based association test. We further explored SNPs in two genes that regulate p53 stability: MDM2 (SNP309) and NQO1 (SNP609, SNP465). We also examined the relationship between host genotype and tumor HPV type. We genotyped 577 patients and their biological parents and/or siblings, using PCR-RFLP or Taqman assays. HPVs were typed by sequence-based methods. The transmission/disequilibrium test was used to detect disease-susceptibility alleles. The arginine peptide of TP53 codon 72 was overtransmitted in Caucasian families (P = 0.043), and the significance of this finding was enhanced in a subgroup of women infected with HPV16- and/or HPV18-related HPVs (P = 0.026). Allele C of NQO1 SNP609 was also overtransmitted in all cases (P = 0.026). We found no association between MDM2 SNP309 or NQO1 SNP465 and cervical cancer. Our results indicate that functional polymorphisms in TP53 codon 72 and NQO1 SNP609 associate with the risk of cervical cancer especially in women infected with type 16- and/or type 18-related HPVs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200430      PMCID: PMC2837516          DOI: 10.1158/1055-9965.EPI-09-0886

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Codon 72 polymorphism of the TP53 gene.

Authors:  S Ara; P S Lee; M F Hansen; H Saya
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

2.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

3.  Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects.

Authors:  Yoshimitsu Niwa; Kaoru Hirose; Toru Nakanishi; Akihiro Nawa; Kazuo Kuzuya; Kazuo Tajima; Nobuyuki Hamajima
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

4.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

5.  Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck.

Authors:  Asher Begleiter; Alia Norman; Darren Leitao; Teresa Cabral; Donna Hewitt; Sushu Pan; Jennifer R Grandis; Jill M Siegfried; Samy El-Sayed; Donna Sutherland; David A Ross; Paul D Kerr
Journal:  Oral Oncol       Date:  2005-10       Impact factor: 5.337

6.  NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.

Authors:  Chun Chao; Zuo-Feng Zhang; Julien Berthiller; Paolo Boffetta; Mia Hashibe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-05       Impact factor: 4.254

Review 7.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans.

Authors:  G L Bond; A J Levine
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

8.  Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma.

Authors:  Jason D Wright; Jianduan Li; Daniela S Gerhard; Zhengyan Zhang; Phyllis C Huettner; Matthew A Powell; Randall K Gibb; Thomas J Herzog; David G Mutch; Kathryn M Trinkaus; Janet S Rader
Journal:  Gynecol Oncol       Date:  2005-07       Impact factor: 5.482

9.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

10.  No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency.

Authors:  V A Govan; S Loubser; D Saleh; M Hoffman; A-L Williamson
Journal:  Int J Immunogenet       Date:  2007-06       Impact factor: 1.466

View more
  24 in total

1.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

2.  Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer.

Authors:  Zhi-Hui Yan; Li-Hong Cui; Xiao-Hui Wang; Chao Li; Xing He
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India.

Authors:  Raju K Mandal; Kamran Nissar; Rama D Mittal
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

4.  Identification and validation of a prognostic proteomic signature for cervical cancer.

Authors:  Janet S Rader; Amy Pan; Bradley Corbin; Marissa Iden; Yiling Lu; Christopher P Vellano; Rehan Akbani; Gordon B Mills; Pippa Simpson
Journal:  Gynecol Oncol       Date:  2019-08-30       Impact factor: 5.482

5.  TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

Authors:  Ana Coelho; Augusto Nogueira; Sílvia Soares; Joana Assis; Deolinda Pereira; Isabel Bravo; Raquel Catarino; Rui Medeiros
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

6.  Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis.

Authors:  Raju K Mandal; Sandhya Dubey; Aditya K Panda; Rama D Mittal
Journal:  Tumour Biol       Date:  2014-03-28

7.  Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.

Authors:  Fang Yuan; Ruifen Sun; Peng Chen; Yundan Liang; Shanshan Ni; Yi Quan; Juan Huang; Lin Zhang; Linbo Gao
Journal:  Tumour Biol       Date:  2015-11-30

8.  Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer.

Authors:  Duanduan Ma; Raymond L Hovey; Zhengyan Zhang; Samantha Fye; Phyllis C Huettner; Ingrid B Borecki; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-08-06       Impact factor: 5.482

Review 9.  Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes.

Authors:  Shing Cheng Tan; Ravindran Ankathil
Journal:  Tumour Biol       Date:  2015-08-05

10.  MDM2 SNP309 variation increases cervical cancer risk among Asians.

Authors:  Xianlu Zhuo; Jie Ren; Dairong Li; Yongzhong Wu; Qi Zhou
Journal:  Tumour Biol       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.